An announcement from Akeso, Inc. ( (HK:9926) ) is now available. Akeso, Inc. has announced that its board of directors will meet on August 26, 2025, to consider and approve the interim results for ...

Summit Therapeutics posts wider-than-expected second-quarter loss as ivonescimab trials advance in multiple lung cancer settings.

Summit Therapeutics, which has consistently been communicating quarterly results through investor calls in the past few years ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its multicenter, randomized, double-blind Phase III study (AK112-311/HARMONi-9), evaluating ...

Guangzhou Development District, also known as Huangpu district of Guangzhou, capital of Guangdong province, is offering a ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that its global, multicenter, randomized Phase II registrational trial (COMPASSION-36/AK104-225) has been approved to initiate by both ...

A PD-L1xVEGF bispecific antibody from China’s ImmuneOnco Biopharmaceuticals has shown early promise in shrinking lung tumors, ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its pivotal Phase III clinical study (AK112-305/HARMONi-8A) of ivonescimab (PD-1/VEGF bispecific ...

With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic ...

Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological ...

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

HONG KONG, July 24, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been enrolled in the pivotal/registration Phase III clinical ...